Short answer
GeneDx Holdings Corp. (WGS) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $123M (up 5.4% year over year) with net income of −$12M.
Q3 2026 key financials · XBRL
- Revenue
- $123M
- +5.4% YoY · +7.6% QoQ
- Net income
- −$12M
- −61.5% YoY · +30.5% QoQ
- Operating margin
- -8.5%
- Gross margin
- 69.9%
- EPS (diluted)
- −$0.40
- −53.8% YoY · +32.2% QoQ
Source: XBRL data from the GeneDx Holdings Corp. (WGS) Q3 2026 10-Q on SEC EDGAR. USD.
GeneDx Holdings Corp. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $123.1M, up 5% YoY from $116.7M, driven by diagnostic test revenue of $120.1M
- Gross margin 69.9% vs 72.4% YoY, with net loss $12.3M vs $7.6M
- Best performer: whole exome and genome sequencing revenue up 12%, test volumes up 25%
- Cash and securities $170.1M; operating cash flow $(72.0)M vs $36.4M YoY
- Capital deployment: $150.0M Blackstone borrowing, $5.0M stock issuance, $21.8M property and software investment
Risk Factors
- New PAMA rate risk triggered by September 2026 preliminary weighted medians, with many codes facing reductions beginning January 1, 2027
- Most material update: cumulative PAMA cuts could continue through 2029, increasing aggregate financial impact over the phase-in period
- Regulatory risk: laboratories face substantial civil money penalties for failing to report or erroneously reporting private-payor data
- Revenue risk: Medicare coverage represents a significant patient base, making CMS reimbursement reductions especially impactful
- Policy uncertainty: Congress may enact the RESULTS Act or other PAMA reforms before January 1, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GeneDx Holdings Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.